SpyGlass Pharma, Inc. (SGP) income statement
SGPNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$29.68−1.75 (-5.58%)
Close on Nov 18, 2026Market cap $992.74MP/E –Yield –
SpyGlass Pharma, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- 50.1%
Financial strength
- Current ratio
- 25.06
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 2364.6%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 4.27
- Dividend yield
- –
See a number that looks wrong?